Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2015

View Archived Issues

Ono Pharmaceutical presents novel LPA1 receptor antagonist for BPH

Susceptibility gene for adolescent idiopathic scoliosis identified

CSL Behring enrolls first patient in phase II/III study of rVIIa-FP

Herbal preparation HAT-01 more effective than calcipotriol in psoriasis patients

Merck KGaA and Cancer Research UK report development of Wnt signaling inhibitors

Clementia Pharmaceuticals expands ongoing phase II study of palovarotene

Tapros approved for open-angle glaucoma and ocular hypertension in China

Daiichi Sankyo discloses novel UR-2 receptor antagonists

Amgen submits NDA for etelcalcetide

Lundbeck discloses PDE1 inhibitors

Taiho patents JAK3 inhibitors

Axxam divulges P2X7 antagonists

MedoLution introduces T790M EGFR kinase inhibitors

Oncothyreon patents Chk1 inhibitors

Vitae Pharmaceuticals discloses ROR-gamma inhibitors

FDA grants orphan drug designation to Toca-511/Toca-FC for glioblastoma

PREVENT and Vaxent start phase I trial of multivalent Group A Streptococcus vaccine

MorphoSys and Immatics Biotechnologies establish strategic alliance in cancer

Covance enters into agreement with leading pharmaceutical company for clinical trial monitoring

Hospira and Cerner expand technology agreement

New company Immatics US established to develop adoptive cellular therapies

Asthma exacerbation rates not reduced in tralokinumab trial

Ono Pharmaceutical seeks Japanese approval for carfilzomib

Tracleer approved in Japan for new digital ulcers in patients with systemic scleroderma

European marketing authorization granted for Respreeza

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...